November 13, 2019 

Palo Alto, California – (Business Wire) – November 13, 2019 – LifeMax Laboratories, Inc. (“LifeMax”), a private company ...

LifeMax Receives Orphan Drug Designation From the European...

December 3, 2018 

Palo Alto, California – (Business Wire) – December 03, 2018 – LifeMax Laboratories, Inc. (“LifeMax”), a private company ...

LifeMax Appoints Kirk Johnson, Ph.D., as VP of Preclinical Development

July 18, 2019 

Palo Alto, California – (Business Wire) – July 18, 2019 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused ...

LifeMax Receives Rare Pediatric Disease Designation For LM-030 ...

September 13, 2018 

Palo Alto, California – (Business Wire) – September 13, 2018 – LifeMax Laboratories, Inc. (“LifeMax”), a private company ...

LifeMax Appoints Laman Alani, Ph.D., as VP of Product Development

June 27, 2019 

Palo Alto, California – (Business Wire) – June 27, 2019 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused ...

LifeMax Receives Orphan Drug Designation From the United States Food & ...

August 27, 2018 

Palo Alto, California – (Business Wire) - August 27, 2018 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused ...

LifeMax Acquires Worldwide Right to Clinical Stage Orphan Asset

Taking on Greater Challenges of Unmet Medical Needs by Treating Diseases with Few or No Therapeutic Options.

©2019 BY LIFEMAX HEALTHCARE INTERNATIONAL